DOCSLIB.ORG

State and Specialty Pharmacy Drug Reimbursement Rates

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
State and Specialty Pharmacy Drug Reimbursement Rates State and Specialty Pharmacy Drug Reimbursement The following table lists specialty pharmacy drug reimbursement rates. ForwardHealth defines specialty drugs as drugs requiring comprehensive patient care services, clinical management, and product support services. Drugs that meet ForwardHealth’s definition of specialty drugs will be reimbursed using the following rates. However, these rates do not apply to specialty drugs purchased through the federal 340B Drug Discount Program, which will be reimbursed according to the 340B ingredient cost reimbursement methodology. If ForwardHealth uses State Maximum Allowable Cost (SMAC) reimbursement in the future, the SMAC reimbursement rates will be published in this table. Effective 04/01/2021 EAC* EAC* Label Generic Name - Label - Generic ANEMIA/NEUTROPENIA DRUGS ARANESP DARBEPOETIN ALFA IN POLYSORBAT -1.0% EPOGEN EPOETIN ALFA -1.6% FULPHILA PEGFILGRASTIM-JMDB -1.0% GRANIX TBO-FILGRASTIM -1.0% MIRCERA METHOXY PEG-EPOETIN BETA -0.4% NEULASTA PEGFILGRASTIM -1.0% NEUPOGEN FILGRASTIM -1.0% NIVESTYM FILGRASTIM-AAFI -1.0% PROCRIT EPOETIN ALFA -1.6% RETACRIT EPOETIN ALFA-EPBX -1.0% UDENYCA PEGFILGRASTIM-CBQV -1.0% ZARXIO FILGRASTIM-SNDZ -1.0% ZIEXTENZO PEGFILGRASTIM-BMEZ -1.0% ANTICOAGULANT DRUGS ARIXTRA FONDAPARINUX SODIUM -3.0% -50.0% FONDAPARINUX SODIUM FONDAPARINUX SODIUM -50.0% FRAGMIN DALTEPARIN SODIUM,PORCINE -0.4% THROMBATE III ANTITHROMBIN III (PLASMA DER) -0.4% ANTI-INFECTIVE DRUGS ABELCET AMPHOTERICIN B LIPID COMPLEX -0.4% AMBISOME AMPHOTERICIN B LIPOSOME -0.4% ANCOBON FLUCYTOSINE -0.4% -1.0% AVYCAZ CEFTAZIDIME/AVIBACTAM -0.4% CRESEMBA ISAVUCONAZONIUM SULFATE -0.4% CUBICIN DAPTOMYCIN -0.4% -1.0% CUBICIN RF DAPTOMYCIN -0.4% -1.0% DALVANCE DALBAVANCIN HCL -0.4% DAPTOMYCIN DAPTOMYCIN -1.0% FLUCYTOSINE FLUCYTOSINE -1.0% IMPAVIDO MILTEFOSINE -0.4% LINEZOLID IN 0.9% SODIUM CHLOR LINEZOLID IN 0.9% SODIUM CHLOR -0.4% LINEZOLID IN DEXTROSE 5% LINEZOLID IN DEXTROSE 5% -40.0% LINEZOLID ORAL LINEZOLID ORAL -40.0% ORBACTIV ORITAVANCIN DIPHOSPHATE -0.4% PENTAM 300 PENTAMIDINE ISETHIONATE -0.4% -1.0% PENTAMIDINE ISETHIONATE PENTAMIDINE ISETHIONATE -1.0% SIVEXTRO TEDIZOLID PHOSPHATE -0.4% SYNERCID QUINUPRISTIN/DALFOPRISTIN -0.4% VIBATIV TELAVANCIN HCL -0.4% ZYVOX IN DEXTROSE 5% LINEZOLID IN DEXTROSE 5% -0.4% -40.0% ZYVOX ORAL LINEZOLID ORAL -0.4% -40.0% BLOOD CELL DEFICIENCY DRUGS DOPTELET AVATROMBOPAG MALEATE -0.4% LEUKINE SARGRAMOSTIM -1.0% MULPLETA LUSUTROMBOPAG -0.4% NPLATE ROMIPLOSTIM -0.4% PROMACTA ELTROMBOPAG OLAMINE -1.0% ENDOCRINE DISORDER DRUGS BYNFEZIA OCTREOTIDE ACETATE -0.4% MYALEPT METRELEPTIN -0.4% MYCAPSSA OCTREOTIDE ACETATE -0.4% OCTREOTIDE ACETATE OCTREOTIDE ACETATE -1.0% OCTREOTIDE ACETATE OCTREOTIDE ACETATE -30.0% SANDOSTATIN OCTREOTIDE ACETATE -30.0% -1.0% SIGNIFOR PASIREOTIDE DIASPARTATE -0.4% SOMATULINE DEPOT LANREOTIDE ACETATE -0.4% SOMAVERT PEGVISOMANT -0.4% ENZYME DEFICIENCY DRUGS ADAGEN PEGADEMASE BOVINE 1.0% ALDURAZYME LARONIDASE 1.0% AMMONUL SODIUM BENZOATE/SOD PHENYLACET 1.0% -10.0% CARBAGLU CARGLUMIC ACID 1.0% CERDELGA ELIGLUSTAT TARTRATE 1.0% FABRAZYME AGALSIDASE BETA 1.0% GALAFOLD MIGALASTAT HCL 1.0% KUVAN SAPROPTERIN DIHYDROCHLORIDE -0.7% -0.1% KUVAN SAPROPTERIN DIHYDROCHLORIDE -0.7% -1.0% MEPSEVII VESTRONIDASE ALFA-VJBK 1.0% MIGLUSTAT MIGLUSTAT -10.0% NAGLAZYME GALSULFASE 1.0% NITYR NITISINONE 1.0% ORFADIN NITISINONE 1.0% PALYNZIQ PEGVALIASE-PQPZ 1.0% SAPROPTERIN DIHYDROCHLORIDE SAPROPTERIN DIHYDROCHLORIDE -0.1% State and Specialty Pharmacy Drug Reimbursement ENZYME DEFICIENCY DRUGS CONT. SAPROPTERIN DIHYDROCHLORIDE SAPROPTERIN DIHYDROCHLORIDE -1.0% SODIUM BENZOATE/SOD PHENYLACET SODIUM BENZOATE/SOD PHENYLACET -10.0% STRENSIQ ASFOTASE ALFA 1.0% ZAVESCA MIGLUSTAT 1.0% -10.0% GROWTH HORMONE DRUGS EGRIFTA SV TESAMORELIN ACETATE -1.6% GENOTROPIN SOMATROPIN -2.0% HUMATROPE SOMATROPIN -2.0% INCRELEX MECASERMIN -1.6% NORDITROPIN FLEXPRO SOMATROPIN -2.0% NUTROPIN AQ NUSPIN SOMATROPIN -2.0% OMNITROPE SOMATROPIN -2.0% SAIZEN SOMATROPIN -2.0% SAIZEN-SAIZENPREP SOMATROPIN -2.0% SEROSTIM SOMATROPIN -2.0% ZOMACTON SOMATROPIN -2.0% ZORBTIVE SOMATROPIN -2.0% HEMOPHILIA DRUGS ADVATE ANTIHEMOPHIL.FVIII,FULL LENGTH -22.0% ADYNOVATE ANTIHEMO.FVIII,FULL LENGTH PEG -12.0% AFSTYLA ANTIHEM.FVIII,SIN-CHN,B-DM TRU -15.0% ALPHANATE ANTIHEMOPHILIC FACTOR/VWF -20.0% ALPHANINE SD FACTOR IX -20.0% ALPROLIX FACTOR IX REC, FC FUSION PROTN -4.0% BENEFIX FACTOR IX HUMAN RECOMBINANT -15.0% COAGADEX COAGULATION FACTOR X -10.0% CORIFACT FACTOR XIII -10.0% ELOCTATE ANTIHEMOPH.FVIII REC,FC FUSION -9.0% ESPEROCT FVIII REC,B-DOM TRUNC PEG-EXEI -10.0% FEIBA NF ANTI-INHIBITOR COAGULANT COMP. -15.0% HELIXATE FS ANTIHEMOPHIL.FVIII,FULL LENGTH -22.0% HEMLIBRA EMICIZUMAB-KXWH -6.0% HEMOFIL M ANTIHEMOPHILIC FACTOR, HUMAN -20.0% HUMATE-P ANTIHEMOPHILIC FACTOR/VWF -18.0% IDELVION FACTOR IX RECOM,ALBUMIN FUSION -4.0% IXINITY FACTOR IX HUMAN RECOMB,THR 148 -5.0% JIVI FVIII REC,B-DOM DELET PEG-AUCL -10.0% KOATE ANTIHEMOPHILIC FACTOR, HUMAN -15.0% KOGENATE FS ANTIHEMOPHIL.FVIII,FULL LENGTH -22.0% KOVALTRY ANTIHEMOPHIL.FVIII,FULL LENGTH -22.0% MONONINE FACTOR IX -20.0% NOVOEIGHT ANTIHEMOPH.FVIII,B-DOM TRUNCAT -15.0% NOVOSEVEN RT COAGULATION FACTOR VIIA,RECOMB -12.0% NUWIQ ANTIHEMOPH.FVIII,HEK B-DELETE -12.0% OBIZUR ANTIHEMOPHILIC FVIII,REC PORC 0.0% PROFILNINE FACTOR IX CPLX(PCC)NO4,3FACTOR -10.0% REBINYN FACTOR IX HUMAN REC,PEGYLATED -5.0% RECOMBINATE ANTIHEMOPHILIC FACTOR, HUM REC -15.0% RIASTAP FIBRINOGEN -10.0% RIXUBIS FACTOR IX HUMAN RECOMBINANT -15.0% STIMATE DESMOPRESSIN ACETATE 0.0% TRETTEN FACTOR XIII A-SUBUNIT,RECOMB -10.0% VONVENDI VON WILLEBRAND FACTOR -10.0% WILATE ANTIHEMOPHILIC FACTOR/VWF -15.0% XYNTHA ANTIHEMOPH.FVIII,B-DOMAIN DEL -20.0% XYNTHA SOLOFUSE ANTIHEMOPH.FVIII,B-DOMAIN DEL -20.0% HEPATITIS DRUGS ADEFOVIR DIPIVOXIL ADEFOVIR DIPIVOXIL -10.0% BARACLUDE SOLUTION ENTECAVIR SOLUTION -1.0% BARACLUDE TABLET ENTECAVIR TABLET -1.0% -40.0% ENTECAVIR TABLET ENTECAVIR TABLET -40.0% EPCLUSA SOFOSBUVIR/VELPATASVIR -2.0% EPIVIR HBV SOLUTION LAMIVUDINE SOLUTION -2.5% EPIVIR HBV TABLET LAMIVUDINE TABLET -2.5% -60.0% HARVONI LEDIPASVIR/SOFOSBUVIR -2.0% HEPSERA ADEFOVIR DIPIVOXIL -1.0% -10.0% INTRON A INTERFERON ALFA-2B,RECOMB. -0.4% LAMIVUDINE TABLET LAMIVUDINE TABLET -60.0% LEDIPASVIR-SOFOSBUVIR LEDIPASVIR/SOFOSBUVIR -2.0% MAVYRET GLECAPREVIR/PIBRENTASVIR -3.0% MODERIBA RIBAVIRIN -50.0% PEGASYS PEGINTERFERON ALFA-2A -1.6% PEGINTRON PEGINTERFERON ALFA-2B -1.6% RIBASPHERE RIBAVIRIN -50.0% SOFOSBUVIR-VELPATASVIR SOFOSBUVIR/VELPATASVIR -2.0% SOVALDI SOFOSBUVIR -2.0% VEMLIDY TENOFOVIR ALAFENAMIDE -2.0% VOSEVI SOFOSBUVIR/VELPATAS/VOXILAPREV -3.0% ZEPATIER ELBASVIR/GRAZOPREVIR -2.0% HEREDITARY ANGIOEDEMA DRUGS BERINERT C1 ESTERASE INHIBITOR -0.4% CINRYZE C1 ESTERASE INHIBITOR -0.4% FIRAZYR ICATIBANT ACETATE -0.4% -5.0% HAEGARDA C1 ESTERASE INHIBITOR -0.4% ICATIBANT ACETATE ICATIBANT ACETATE -5.0% ORLADEYO BEROTRALSTAT HYDROCHLORIDE -0.4% RUCONEST C1 ESTERASE INHIBITOR, RECOMB -0.4% State and Specialty Pharmacy Drug Reimbursement HEREDITARY ANGIOEDEMA DRUGS CONT. TAKHZYRO LANADELUMAB-FLYO -0.4% IMMUNE DEFICIENCY DRUGS ACTIMMUNE INTERFERON GAMMA-1B,RECOMB. -0.4% ASCENIV IMMUNE GLOBULIN,GAMMA(IGG)SLRA -20.0% BIVIGAM IMMUN GLOB G(IGG)/GLY/IGA OV50 -0.4% CUTAQUIG IMMUN GLOB G(IGG)-HIPP/MALTOSE -0.4% CUVITRU IMMUN GLOB G(IGG)/GLY/IGA OV50 -5.0% FLEBOGAMMA DIF IMM GLOB G (IGG)/SORB/IGA 0-50 -5.0% GAMMAGARD LIQUID IMMUN GLOB G(IGG)/GLY/IGA OV50 -20.0% GAMMAKED IMMUNE GLOBUL G/GLY/IGA AVG 46 -20.0% GAMMAPLEX IMMUN GLOB G(IGG)/GLY/IGA 0-50 -20.0% GAMMAPLEX IMMUN GLOB G/SORB/GLY/IGA 0-50 -20.0% GAMUNEX-C IMMUNE GLOBUL G/GLY/IGA AVG 46 -20.0% HIZENTRA IMMUN GLOB G(IGG)/PRO/IGA 0-50 -20.0% HYQVIA IGG/HYALURONIDASE,RECOMBINANT -20.0% OCTAGAM IMMUN GLOBG(IGG)/MALT/IGA OV50 -20.0% PANZYGA IMMUN GLOB G(IGG)-IFAS/GLYCINE -0.4% PRIVIGEN IMMUN GLOB G(IGG)/PRO/IGA 0-50 -20.0% XEMBIFY IMMUNE GLOBULIN,GAMMA(IGG)KLHW -5.0% LIPITROPICS, OTHER DRUGS JUXTAPID LOMITAPIDE MESYLATE -0.4% PRALUENT PEN ALIROCUMAB -0.4% REPATHA PUSHTRONEX EVOLOCUMAB -0.4% REPATHA SURECLICK EVOLOCUMAB -0.4% REPATHA SYRINGE EVOLOCUMAB -0.4% MISC.: IRON DEFICIENCY DRUGS FERAHEME FERUMOXYTOL -0.4% MISC: HYPOCALCEMIA DRUGS CALCITRIOL CALCITRIOL -10.0% MISC: IRON OVERLOAD DRUGS DEFERASIROX DEFERASIROX -5.0% EXJADE DEFERASIROX -0.4% -5.0% FERRIPROX DEFERIPRONE -0.4% FERRIPROX (2 TIMES A DAY) DEFERIPRONE -0.4% JADENU DEFERASIROX -0.4% -5.0% JADENU SPRINKLE DEFERASIROX -0.4% MISCELLANEOUS: INJECTABLE & OTHER ROUTE DRUGS GATTEX TEDUGLUTIDE -0.4% RAVICTI GLYCEROL PHENYLBUTYRATE -0.4% MULTIPLE SCLEROSIS DRUGS AMPYRA DALFAMPRIDINE -1.6% -30.0% AUBAGIO TERIFLUNOMIDE -1.0% AVONEX INTERFERON BETA-1A -2.0% AVONEX INTERFERON BETA-1A/ALBUMIN -2.0% AVONEX PEN INTERFERON BETA-1A -2.0% BAFIERTAM MONOMETHYL FUMARATE -1.6% BETASERON INTERFERON BETA-1B -2.0% COPAXONE GLATIRAMER ACETATE -2.6% -30.0% DALFAMPRIDINE DALFAMPRIDINE -30.0% DIMETHYL FUMARATE DIMETHYL FUMARATE -5.0% EXTAVIA INTERFERON BETA-1B -2.0% GILENYA FINGOLIMOD HCL -2.6% GLATIRAMER ACETATE GLATIRAMER ACETATE -30.0% GLATOPA GLATIRAMER ACETATE -2.6% -30.0% KESIMPTA PEN OFATUMUMAB -1.6% MAVENCLAD CLADRIBINE -1.6% MAYZENT SIPONIMOD -1.6% PLEGRIDY PEGINTERFERON BETA-1A -1.6% PLEGRIDY PEN PEGINTERFERON BETA-1A -1.6% REBIF INTERFERON BETA-1A/ALBUMIN -2.0% REBIF REBIDOSE INTERFERON BETA-1A/ALBUMIN -2.0% TECFIDERA DIMETHYL FUMARATE -1.6% -5.0% VUMERITY DIROXIMEL FUMARATE -1.6% ZEPOSIA OZANIMOD HYDROCHLORIDE -1.6% ONCOLOGY - ADJUNCT THERAPY DRUGS LEUCOVORIN CALCIUM LEUCOVORIN CALCIUM -1.0% MESNEX MESNA -0.4% VARUBI ROLAPITANT HCL -0.4% ZOLEDRONIC ACID ZOLEDRONIC ACID -20.0% ZUPLENZ ONDANSETRON -0.4% ONCOLOGY - ORAL DRUGS ABIRATERONE ACETATE ABIRATERONE ACETATE -50.0% AFINITOR EVEROLIMUS -0.4% AFINITOR EVEROLIMUS -0.4% -1.0% AFINITOR DISPERZ EVEROLIMUS -0.4% ALECENSA ALECTINIB HCL -0.4% ALKERAN MELPHALAN -0.4% -10.0% ALUNBRIG BRIGATINIB -0.4% AYVAKIT AVAPRITINIB -0.4% BALVERSA ERDAFITINIB -0.4% BEXAROTENE BEXAROTENE -10.0% BOSULIF BOSUTINIB -1.0% BRAFTOVI ENCORAFENIB -0.4% BRUKINSA ZANUBRUTINIB -0.4% CABOMETYX CABOZANTINIB S-MALATE -0.4% CALQUENCE ACALABRUTINIB -0.4% CAPECITABINE CAPECITABINE -25.0% State and Specialty Pharmacy Drug Reimbursement ONCOLOGY - ORAL DRUGS CONT.
Load more

Recommended publications
  • A Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
    NCT# 01596699 A Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation Protocol Number: CC #110819 Version Number: 7.0 Version Date: June 6, 2013 Study Drug: Clofarabine Principal Investigator (Sponsor-Investigator) Christopher C. Dvorak, MD Co-Investigators Janel Long-Boyle, PharmD, PhD Morton Cowan, MD Biljana Horn, MD James Huang, MD Robert Goldsby, MD Kristin Ammon, MD Justin Wahlstrom, MD Statistician Stephen Shiboski, PhD Clinical Research Coordinator Revision History Version #1.0 9/19/11 Version #2.0 11/8/11 Version #3.1 02/23/12 Version #4.0 04/10/12 Version #5.0 04/30/12 Version #6.0 08/09/12 Version #7.0 06/07/13 Clofarabine Version 4.0, 04/10/12 Page 1 of 33 1.0 Hypothesis and Specific Aims: 1.1 Hypothesis: The addition of Clofarabine to standard Busulfan and Fludarabine prior to allogeneic hematopoietic cell transplant (HCT) will be safe and will improve engraftment rates of children with non-malignant diseases or decrease relapse rates of patients with high-risk myeloid malignancies. 1.2 Specific Aims: 1.2.1 Primary Objective: To determine the toxicity of the addition of Clofarabine to a conditioning backbone of Busulfan plus Fludarabine in patients with myeloid malignancies and non-malignant diseases undergoing allogeneic HCT. 1.2.2 Secondary Objectives: a. To determine if the addition of Clofarabine to a conditioning backbone of Busulfan plus Fludarabine improves the engraftment rate of patients with non-malignant diseases (Stratum A) undergoing allogeneic HCT as compared to historic controls.
    [Show full text]
  • Duvelisib Eliminates CLL B Cells, Impairs CLL- Supporting Cells, and Overcomes Ibrutinib Resistance in Preclinical Models
    Duvelisib Eliminates CLL B Cells, Impairs CLL- Supporting Cells, and Overcomes Ibrutinib Resistance in Preclinical Models Shih-Shih Chen ( [email protected] ) Karches Center for Oncology Research, the Feinstein Institutes for Medical Research Jacqueline Barrientos Karches Center for Oncology Research, the Feinstein Institutes for Medical Research Gerardo Ferrer Josep Carreras Leukaemia Research Institute (IJC) https://orcid.org/0000-0002-4084-6815 Priyadarshini Ravichandran Karches Center for Oncology Research, the Feinstein Institutes for Medical Research Michael Ibrahim Karches Center for Oncology Research, the Feinstein Institutes for Medical Research Yasmine Kieso Karches Center for Oncology Research, the Feinstein Institutes for Medical Research Jeff Kutok Innity Pharmaceuticals Marisa Peluso Innity Pharmaceuticals, Inc Sujata Sharma Innity Pharmaceuticals, Inc David Weaver Institute of Health Sciences, Anhui University Jonathan Pachter Verastem Inc. Kanti Rai The Karches Center for Oncology Research. The Feinstein Institutes for Medical Research. Nicholas Chiorazzi Karches Center for Oncology Research, the Feinstein Institutes for Medical Research Article Keywords: chronic lymphocytic leukemia, cancer therapy, Bruton’s Tyrosine Kinase (BTKi), phosphoinositide 3-kinase (PI3Ki) Page 1/23 Posted Date: July 21st, 2021 DOI: https://doi.org/10.21203/rs.3.rs-701669/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/23 Abstract Inhibitors of Bruton’s Tyrosine Kinase (BTKi) and phosphoinositide 3-kinase (PI3Ki) have signicantly improved therapy of chronic lymphocytic leukemia (CLL). However, the emergence of resistance to BTKi has introduced an unmet therapeutic need. Here we demonstrate in vitro and in vivo the essential roles of PI3K-δ for CLL B-cell survival and migration and of PI3K-γ in T-cell migration and macrophage polarization; and more ecacious inhibition in CLL-cell burden by dual inhibition of PI3K-δ,γ.
    [Show full text]
  • PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
    International Journal of Molecular Sciences Review PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects Rosalin Mishra , Hima Patel, Samar Alanazi , Mary Kate Kilroy and Joan T. Garrett * Department of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267-0514, USA; [email protected] (R.M.); [email protected] (H.P.); [email protected] (S.A.); [email protected] (M.K.K.) * Correspondence: [email protected]; Tel.: +1-513-558-0741; Fax: +1-513-558-4372 Abstract: The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian, colorectal, prostate, glioblastoma and endometrial cancers. PI3K signaling plays an important role in cancer cell survival, angiogenesis and metastasis, making it a promising therapeutic target. There are several ongoing and completed clinical trials involving PI3K inhibitors (pan, isoform-specific and dual PI3K/mTOR) with the goal to find efficient PI3K inhibitors that could overcome resistance to current therapies. This review focuses on the current landscape of various PI3K inhibitors either as monotherapy or in combination therapies and the treatment outcomes involved in various phases of clinical trials in different cancer types. There is a discussion of the drug-related toxicities, challenges associated with these PI3K inhibitors and the adverse events leading to treatment failure. In addition, novel PI3K drugs that have potential to be translated in the clinic are highlighted. Keywords: cancer; PIK3CA; resistance; PI3K inhibitors Citation: Mishra, R.; Patel, H.; Alanazi, S.; Kilroy, M.K.; Garrett, J.T.
    [Show full text]
  • The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands
    The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands Clare Louise Wishart Submitted in accordance with the requirements for the degree of Doctor of Philosophy of Science University of Leeds School of Biomedical Sciences Faculty of Biological Sciences September 2013 I Intellectual Property and Publication Statements The candidate confirms that the work submitted is her own and that appropriate credit has been given where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement. The right of Clare Louise Wishart to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. © 2013 The University of Leeds and Clare Louise Wishart. II Acknowledgments Firstly I would like to offer my sincerest thanks and gratitude to my supervisor, Dr. Dan Donnelly, who has been nothing but encouraging and engaging from day one. I have thoroughly enjoyed every moment of working alongside him and learning from his guidance and wisdom. My thanks go to my academic assessor Professor Paul Milner whom I have known for several years, and during my time at the University of Leeds he has offered me invaluable advice and inspiration. Additionally I would like to thank my academic project advisor Dr. Michael Harrison for his friendship, help and advice. I would like to thank Dr. Rosalind Mann and Dr. Elsayed Nasr for welcoming me into the lab as a new PhD student and sharing their experimental techniques with me, these techniques have helped me no end in my time as a research student.
    [Show full text]
  • 214120Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 214120Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA Multidisciplinary Review and Evaluation Application Number NDA 214120 Application Type Type 3 Priority or Standard Priority Submit Date 3/3/2020 Received Date 3/3/2020 PDUFA Goal Date 9/3/2020 Office/Division OOD/DHM1 Review Completion Date 9/1/2020 Applicant Celgene Corporation Established Name Azacitidine (Proposed) Trade Name Onureg Pharmacologic Class Nucleoside metabolic inhibitor Formulations Tablet (200 mg, 300 mg) (b) (4) Applicant Proposed Indication/Population Recommendation on Regulatory Regular approval Action Recommended Indication/ For continued treatment of adult patients with acute Population myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. SNOMED CT for the Recommended 91861009 Indication/Population Recommended Dosing Regimen 300 mg orally daily on Days 1 through 14 of each 28-day cycle Reference ID: 4664570 NDA Multidisciplinary Review and Evaluation NDA 214120 Onureg (azacitidine tablets) TABLE OF CONTENTS TABLE OF CONTENTS ................................................................................................................................... 2 TABLE OF TABLES .......................................................................................................................................
    [Show full text]
  • Minutes of the CHMP Meeting 14-17 September 2020
    13 January 2021 EMA/CHMP/625456/2020 Corr.1 Human Medicines Division Committee for medicinal products for human use (CHMP) Minutes for the meeting on 14-17 September 2020 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes Disclaimers Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). 1 Addition of the list of participants Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • List of Approved Ndas for Biological Products That Were Deemed to Be Blas on March 23, 2020
    List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020 On March 23, 2020, an approved application for a biological product under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) was deemed to be a license for the biological product under section 351 of the Public Health Service Act (PHS Act) (see section 7002(e)(4)(A) of the Biologics Price Competition and Innovation Act of 2009). To enhance transparency and facilitate planning for the March 23, 2020, transition date, FDA compiled a preliminary list of approved applications for biological products under the FD&C Act that were listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) and that would be affected by this transition provision. FDA posted this list on the FDA website in December 2018, and periodically updated this list before the March 23, 2020, transition date. The September 2019 update to this preliminary list added certain administratively closed applications related to approved applications for biological products that were on the December 2018 version of this list. The January 2020 update to the preliminary list reflected a change to the definition of “biological product” made by the Further Consolidated Appropriations Act, 2020, which was enacted on December 20, 2019. Section 605 of this Act further amended the definition of a “biological product” in section 351(i) of the PHS Act to remove the parenthetical “(except any chemically synthesized polypeptide)” from the statutory category of “protein.” FDA has provided below a list of each approved application for a biological product under the FD&C Act that was deemed to be a license (i.e., an approved biologics license application (BLA)) for the biological product on March 23, 2020.
    [Show full text]
  • A Study of Abemaciclib (LY2835219)
    A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors Status: Not yet recruiting Eligibility Criteria Sex: All Age: up to 18 Years old This study is NOT accepting healthy volunteers Inclusion Criteria: • Body weight ≥10 kilograms and body surface area (BSA) ≥0.5 meters squared. • Participants with any relapsed/refractory malignant solid tumor (excluding lymphoma), including central nervous system tumors, that have progressed on standard therapies and, in the judgment of the investigator, are appropriate candidates for the experimental therapy combination in the study part that is currently enrolling. • Participants must have at least one measurable (per Response Criteria in Solid Tumors [RECIST v1.1; [Eisenhauer et al. 2009] or Response Assessment in Neuro-Oncology (RANO) for central nervous system (CNS) tumors [Wen et al. 2010]) or evaluable lesion. • Participants must have had histologic verification of malignancy at original diagnosis or relapse, except: • Participants with extra-cranial germ-cell tumors who have elevations of serum tumor markers including alpha-fetoprotein or beta- human chorionic gonadotropin (HCG). • Participants with intrinsic brain stem tumors or participants with CNS-germ cell tumors and elevations of CSF or serum tumor markers including alpha-fetoprotein or beta-HCG. • A Lansky score ≥50 for participants ≤16 years of age or Karnofsky score ≥50 for participants >16 years of age. • Participants must have discontinued all previous treatments for cancer or investigational agents and must have recovered from the acute effects to Grade ≤1 at the time of enrollment.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Cancer Drug Pharmacology Table
    CANCER DRUG PHARMACOLOGY TABLE Cytotoxic Chemotherapy Drugs are classified according to the BC Cancer Drug Manual Monographs, unless otherwise specified (see asterisks). Subclassifications are in brackets where applicable. Alkylating Agents have reactive groups (usually alkyl) that attach to Antimetabolites are structural analogues of naturally occurring molecules DNA or RNA, leading to interruption in synthesis of DNA, RNA, or required for DNA and RNA synthesis. When substituted for the natural body proteins. substances, they disrupt DNA and RNA synthesis. bendamustine (nitrogen mustard) azacitidine (pyrimidine analogue) busulfan (alkyl sulfonate) capecitabine (pyrimidine analogue) carboplatin (platinum) cladribine (adenosine analogue) carmustine (nitrosurea) cytarabine (pyrimidine analogue) chlorambucil (nitrogen mustard) fludarabine (purine analogue) cisplatin (platinum) fluorouracil (pyrimidine analogue) cyclophosphamide (nitrogen mustard) gemcitabine (pyrimidine analogue) dacarbazine (triazine) mercaptopurine (purine analogue) estramustine (nitrogen mustard with 17-beta-estradiol) methotrexate (folate analogue) hydroxyurea pralatrexate (folate analogue) ifosfamide (nitrogen mustard) pemetrexed (folate analogue) lomustine (nitrosurea) pentostatin (purine analogue) mechlorethamine (nitrogen mustard) raltitrexed (folate analogue) melphalan (nitrogen mustard) thioguanine (purine analogue) oxaliplatin (platinum) trifluridine-tipiracil (pyrimidine analogue/thymidine phosphorylase procarbazine (triazine) inhibitor)
    [Show full text]
  • Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
    Published OnlineFirst May 23, 2016; DOI: 10.1158/2159-8290.CD-16-0095 RESEARCH ARTICLE Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors Amita Patnaik1, Lee S. Rosen2, Sara M. Tolaney3, Anthony W. Tolcher1, Jonathan W. Goldman2, Leena Gandhi3, Kyriakos P. Papadopoulos1, Muralidhar Beeram1, Drew W. Rasco1, John F. Hilton3, Aejaz Nasir4, Richard P. Beckmann4, Andrew E. Schade4, Angie D. Fulford4, Tuan S. Nguyen4, Ricardo Martinez4, Palaniappan Kulanthaivel4, Lily Q. Li4, Martin Frenzel4, Damien M. Cronier4, Edward M. Chan4, Keith T. Flaherty5, Patrick Y. Wen3, and Geoffrey I. Shapiro3 ABSTRACT We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 and 6, in a multicenter study including phase I dose escalation followed by tumor- specific cohorts for breast cancer, non–small cell lung cancer (NSCLC), glioblastoma, melanoma, and colorectal cancer. A total of 225 patients were enrolled: 33 in dose escalation and 192 in tumor-specific cohorts. Dose-limiting toxicity was grade 3 fatigue. The maximum tolerated dose was 200 mg every 12 hours. The most common possibly related treatment-emergent adverse events involved fatigue and the gastrointestinal, renal, or hematopoietic systems. Plasma concentrations increased with dose, and pharmacodynamic effects were observed in proliferating keratinocytes and tumors. Radiographic responses were achieved in previously treated patients with breast cancer, NSCLC, and melanoma. For hormone receptor–positive breast cancer, the overall response rate was 31%; moreover, 61% of patients achieved either response or stable disease lasting ≥6 months.
    [Show full text]
  • European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa As a Treatment for Patients with Hypophosphatasia
    July 24, 2014 European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia -- Application designated for review under accelerated assessment process -- CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Marketing Authorization Application (MAA) for asfotase alfa, an investigational, first-in-class targeted enzyme replacement therapy for the treatment of hypophosphatasia (HPP), has been validated and granted accelerated assessment by the European Medicines Agency (EMA). The acceptance of this MAA marks the beginning of the review process in the European Union (EU) for this potential new treatment. "HPP is a devastating disease for patients and their families due to progressive deterioration of bones and muscle weakness, which can result in impaired respiratory function, severe disability and death," said Leonard Bell, M.D., Chief Executive Officer of Alexion. "If approved, asfotase alfa would be the first therapy for patients with this life-threatening disorder." The EU filing includes positive data from 68 patients with pediatric-onset HPP (ranging from newborns to 66 years of age) enrolled in three pivotal prospective studies and their extensions, as well as a retrospective natural history study in infants. In April, Alexion initiated the rolling submission of a Biologics License Application (BLA) for asfotase alfa as a treatment for patients with HPP with the U.S. Food and Drug Administration (FDA). About
    [Show full text]